سعر فيمابنت 2.5مجم 14 قرص 2024

Letrozole 2.5 mg film-coated tablets (Penta Pharma, Egypt); pack of 14 tablets (2 strips).

• Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.Population: Postmenopausal womenDailyMed (U.S. National Library of Medicine)
• Extended adjuvant treatment of early breast cancer in postmenopausal women after 5 years of adjuvant tamoxifen.Population: Postmenopausal womenDailyMed (U.S. National Library of Medicine)
• First- and second-line treatment of hormone receptor positive or unknown advanced (locally advanced or metastatic) breast cancer in postmenopausal women.Population: Postmenopausal womenDailyMed (U.S. National Library of Medicine)

• Most common (>20%): hot flashes, arthralgia, flushing, asthenia, oedema, headache, dizziness, hypercholesterolaemia, increased sweating, bone pain and musculoskeletal events.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Pregnancy (can cause fetal harm); known hypersensitivity to letrozole or any excipient.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• May decrease bone mineral density; consider BMD monitoring.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• May increase total cholesterol; consider monitoring serum cholesterol.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Fatigue, dizziness and somnolence may occur; caution when driving or operating machinery.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• TamoxifenCo-administration with tamoxifen 20 mg daily reduced letrozole plasma levels by about 38%.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm and is contraindicated in pregnancy; postmarketing reports describe spontaneous abortions and congenital birth defects, and animal studies showed embryo-fetal toxicity at about 0.1 times the maximum human dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not known whether letrozole is present in human milk; advise not to breastfeed during treatment and for 3 weeks after the last dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Letrozole: Nonsteroidal competitive aromatase inhibitor that binds the heme of the CYP450 subunit of aromatase, lowering estrone and estradiol synthesis without affecting adrenal corticosteroid or aldosterone synthesis (US Femara label).